Adaptin Bio, Inc. (APTN)
OTCMKTS · Delayed Price · Currency is USD
6.27
0.00 (0.00%)
Sep 24, 2026, 3:46 PM EDT
Adaptin Bio Statistics
Total Valuation
Adaptin Bio has a market cap or net worth of 57.89 million. The enterprise value is 57.39 million.
| Market Cap | 57.89M |
| Enterprise Value | 57.39M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Adaptin Bio has 9.23 million shares outstanding. The number of shares has increased by 65.92% in one year.
| Current Share Class | 9.23M |
| Shares Outstanding | 9.23M |
| Shares Change (YoY) | +65.92% |
| Shares Change (QoQ) | +1.69% |
| Owned by Insiders (%) | 33.44% |
| Owned by Institutions (%) | n/a |
| Float | 2.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -34.76 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.37
| Current Ratio | 0.37 |
| Quick Ratio | 0.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -811.63 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -254.74% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 323.56% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.35M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 251 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.39M |
| Pretax Income | -5.40M |
| Net Income | -5.40M |
| EBITDA | n/a |
| EBIT | -5.39M |
| Earnings Per Share (EPS) | -0.63 |
Balance Sheet
The company has 670,488 in cash and 162,208 in debt, with a net cash position of 508,280 or 0.06 per share.
| Cash & Cash Equivalents | 670,488 |
| Total Debt | 162,208 |
| Net Cash | 508,280 |
| Net Cash Per Share | 0.06 |
| Equity (Book Value) | -1.67M |
| Book Value Per Share | -0.18 |
| Working Capital | -1.67M |
Cash Flow
| Operating Cash Flow | -2.52M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | -170,897 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Adaptin Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -65.92% |
| Shareholder Yield | -65.92% |
| Earnings Yield | -9.32% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |